drugset / Trial / NCT05701540

A Study to Evaluate the Efficacy and Safety of Tegoprazan in GERD Patients With Nighttime Heartburn

NCT05701540

Phase 4 Unknown 338 enrolled HK inno.N Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study aims to compare the nighttime heartburn improvement effect of Tegoprazan 50mg and Esomeprazole 40mg(or 20mg) in patients with GERD.

Timeline

Start
2023-03-24
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Esomeprazole Small molecule 20 mg Oral
Comparator Esomeprazole Small molecule 40 mg Oral
Subject Tegoprazan Other / unclassified 50 mg Oral